We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Turmeric Contains Potent Blocker of Head and Neck Cancer

By LabMedica International staff writers
Posted on 29 Sep 2011
Cancer researchers have found recently that curcumin, the main colored component of the spice turmeric, inhibited the activity of the enzyme IKKβ kinase in the saliva of head and neck squamous cell carcinoma cancer (HNSCC) patients, and this inhibition correlated with reduced expression of a number of proinflammatory cytokines.

IKKβ kinase is an enzyme complex that is involved in propagating the cellular response to inflammation. More...
This complex is part of the upstream NF-κB signal transduction cascade. IKKβ kinase specifically phosphorylates an inhibitory protein, and this phosphorylation results in the activation of NF-κB.

Investigators at the University of California, Los Angeles (USA) collected saliva before and after subjects – 21 HNSCC patients and a similar number of healthy individuals - chewed curcumin tablets. Protein was extracted and IKKβ kinase activity measured. Interleukin (IL-6 and IL-8) levels in the salivary supernatants were measured by ELISA.

Results published in the September 15, 2011, edition of the journal Clinical Cancer Research revealed that curcumin treatment led to a reduction in IKKβ kinase activity in the salivary cells of HNSCC patients. Treatment of cultures of UM-SCC1 cancer cells with curcumin as well as with post-curcumin salivary supernatant showed a reduction of IKKβ kinase activity. Curcumin was well tolerated by the patients and resulted in no apparent toxic effects.

At the molecular level, curcumin was found to bind to the IKK enzyme, an inhibitor of IKKβ kinase, and prevented IKKβ kinase from activating the cancer growth promoter NF-κB.

“This study shows that curcumin can work in the mouths of patients with head and neck malignancies and reduce activities that promote cancer growth,” said senior author Dr. Marilene Wang, professor of head and neck surgery at the University of California, Los Angeles. “And it not only affected the cancer by inhibiting a critical cell signaling pathway, it also affected the saliva itself by reducing proinflammatory cytokines within the saliva.”

“The curcumin had a significant inhibitory effect, blocking two different drivers of head and neck cancer growth,” said Dr. Wang. “There is potential here for the development of curcumin as an adjuvant treatment for cancer. It is not toxic, well tolerated, cheap, and easily obtained in any health food store. While this is a promising pilot study, it is important to expand our work to more patients to confirm our findings.”

Related Links:

University of California, Los Angeles




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.